20-F/A: Psyence Biomedical Amends Annual Report to Include Internal Control Statement

Psyence Biomedical Ltd. filed an amendment to its annual report to include the previously omitted management's report on internal control over financial reporting, confirming its effectiveness.

Summary

• Psyence Biomedical Ltd. filed an Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended March 31, 2025.
• The amendment was filed solely to include management's report on internal control over financial reporting under Item 15(b), which was inadvertently omitted from the original filing on June 25, 2025.
• The amendment also includes re-executed certifications required under Section 302 of the Sarbanes-Oxley Act of 2002 (Exhibits 12.1 and 12.2), dated July 25, 2025.
• Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025.
• Management also concluded that the company's internal control over financial reporting was effective as of March 31, 2025.
• There has been no material change in the company's internal control over financial reporting during the fiscal year ended March 31, 2025.
• The company, as a non-accelerated filer, is not required to obtain an attestation report from its independent registered public accounting firm regarding internal control over financial reporting.

Sentiment

Score: 5

Explanation: The filing is neutral in sentiment as it is a procedural amendment to correct an omission and confirms the effectiveness of internal controls, rather than disclosing new financial results or strategic developments.

Positives

• Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025.
• Management concluded that the company's internal control over financial reporting was effective as of March 31, 2025.
• No material changes in internal control over financial reporting occurred during the fiscal year ended March 31, 2025.

Negatives

• Management's report on internal control over financial reporting was inadvertently omitted from the original filing, requiring an amendment.

Risks

• Inherent limitations exist in the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and circumvention or overriding of controls.
• Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

Future Outlook

This amendment does not contain any forward-looking statements or guidance, as it solely addresses the inclusion of a previously omitted report and does not update other disclosures.

Management Comments

• Our management is responsible for establishing and maintaining adequate internal control over financial reporting.
• Internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.
• Based on their evaluation, the Company's CEO and CFO have concluded that, as of the end of the period covered by this Report, the design and operation of the Company's disclosure controls and procedures were effective.
• Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of March 31, 2025.

Industry Context

This filing is a standard procedural amendment related to corporate governance and financial reporting compliance, and it does not provide new information related to broader industry trends or competitive positioning within the biomedical or psychedelic medicine sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides assurance regarding the effectiveness of internal controls over financial reporting, which can enhance confidence in the accuracy and reliability of financial statements.
• Regulatory Authorities: Ensures full compliance with SEC filing requirements by correcting a previous omission.

Key Dates

Keywords

SEC filing, Form 20-F/A, Annual Report Amendment, Internal Control Over Financial Reporting, Disclosure Controls, Sarbanes-Oxley Act, SOX 302 Certification, Psyence Biomedical Ltd., Financial Reporting, Corporate Governance